CRC01

Phase 2Biologic

CCurocell Inc.

CRC01 is one of 56 biologic programs targeting Relapsed Large B-cell Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed Large B-Cell LymphomaRecruiting

Systemic Lupus ErythematosusNot yet recruiting

Relapsed Large B-Cell LymphomaPreclinical

Recruiting

Systemic Lupus ErythematosusPhase 2

Not yet recruiting

Competition

Competitive Landscape

134 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

9 2

Medrol

Pfizer

Phase 3

5 3

Rinvoq

AbbVie

Phase 3

3 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

12 5

Gazyva

Roche

Phase 3

2 6

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

3 7

Rapamune

PPrism Pharmaceuticals

Phase 3

1 8

Ianalumab

Novartis

Phase 3

3 9

Fludara

Sanofi

Phase 2

6 10

Glucocorticoid

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1/2Not yet recruiting

Systemic Lupus Erythematosus

NCT07364396

Q3 2030

PreclinicalRecruiting

Relapsed Large B-Cell Lymphoma

NCT04836507

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus

Not yet recruiting·CCurocell Inc.·Phase 1/2·NCT07364396·39 enrolled

Relapsed Large B-cell Lymphoma1 trial

An Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy of CRC01 in Adult Patients With Relapsed or Refractory Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

Recruiting·CCurocell Inc.·Preclinical·NCT04836507·91 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CRC01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CRC01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CRC01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Curocell Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: CCurocell Inc.

CRC01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Q3 2030

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

Relapsed Large B-cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News